Mammalian target of rapamycin inhibition in polycystic kidney disease: From bench to bedside.
- Author:
Hyun Jung KIM
1
;
Charles L EDELSTEIN
Author Information
1. Division of Renal Diseases and Hypertension, University of Colorado at Denver, Aurora, Colorado, USA. Charles.edelstein@ucdenver.edu
- Publication Type:Review ; Clinical Trial
- Keywords:
Everolimus;
Mammalian target of rapamycin;
Polycystic kidney;
Polycystic kidney disease;
Sirolimus
- MeSH:
Animals;
Dialysis;
Epithelial Cells;
Everolimus;
Genetic Diseases, Inborn;
Humans;
Kidney;
Membranes;
Models, Animal;
New England;
Polycystic Kidney Diseases;
Polycystic Kidney, Autosomal Dominant;
Random Allocation;
Renal Insufficiency, Chronic;
Rodentia;
Sirolimus;
Transplants
- From:Kidney Research and Clinical Practice
2012;31(3):132-138
- CountryRepublic of Korea
- Language:English
-
Abstract:
Autosomal dominant polycystic kidney disease (ADPKD) is the most common life-threatening hereditary disease in the USA resulting in chronic kidney disease and the need for dialysis and transplantation. Approximately 85% of cases of ADPKD are caused by a mutation in the Pkd1 gene that encodes polycystin-1, a large membrane receptor. The Pkd1 gene mutation results in abnormal proliferation in tubular epithelial cells, which plays a crucial role in cyst development and/or growth in PKD. Activation of the proliferative mammalian target of rapamycin (mTOR) signaling pathway has been demonstrated in polycystic kidneys from rodents and humans. mTOR inhibition with sirolimus or everolimus decreases cysts in most animal models of PKD including Pkd1 and Pkd2 gene deficient orthologous models of human disease. On the basis of animal studies, human studies were undertaken. Two large randomized clinical trials published in the New England Journal of Medicine of everolimus or sirolimus in ADPKD patients were very unimpressive and associated with a high side-effect profile. Possible reasons for the unimpressive nature of the human studies include their short duration, the high drop-out rate, suboptimal dosing, lack of randomization of "fast" and "slow progressors" and the lack of correlation between kidney size and kidney function in ADPKD. The future of mTOR inhibition in ADPKD is discussed.
